Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1

Article Biochemical Research Methods

Rational design of a Nivolumab-based ANTI-PD-1 single chain variable fragment that blocks the interaction between PD-1 expressed on T-CELLS and PD-L1 ON CHO cells

Jong Shin et al.

Summary: In this article, a variant of the anti-PD-1 scFv with improved solubility in tissue culture medium is reported. This variant successfully disrupted the interaction between PD-1 and PD-L1.

PROTEIN EXPRESSION AND PURIFICATION (2023)

添加到收藏夹

Article Oncology

Phase 2 Study of the PD-1 Inhibitor Serplulimab Plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma

Zhengang Ren et al.

Summary: This study evaluated the safety and antitumor activity of serplulimab plus HLX04 in patients with previously treated advanced HCC. The results showed that this combination therapy had a manageable safety profile and antitumor activity.

LIVER CANCER (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Envafolimab: First Approval

Anthony Markham

Summary: Envafolimab, a subcutaneously administered single domain anti-PD-L1 antibody, has recently been approved in China for the treatment of various solid tumors and chronic hepatitis B. It has better solubility and tissue penetration than full monoclonal antibodies, allowing for subcutaneous administration.

DRUGS (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Zimberelimab

Margaret Sahu et al.

Summary: Immune checkpoint inhibitors, such as Zimberelimab, have shown potential in the treatment of solid tumors. Zimberelimab exhibits similar activity and selectivity to currently approved PD-1 inhibitors and shows particular benefit in tumors with PD-L1 and TMB positivity. Various early phase clinical trials are investigating its safety and efficacy in different treatment regimens.

DRUGS OF THE FUTURE (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Ming Yi et al.

Summary: Antibodies targeting PD-1/PD-L1 revive immune response against cancer cells, but the low response rate calls for combination therapies. Combining with chemotherapy, radiotherapy, and other treatments can achieve better outcomes, and individualized combination selection is needed to overcome treatment resistance.

MOLECULAR CANCER (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy

Ui Beom Park et al.

Summary: This study reports the crystal structure of the extracellular domain of PD-1 in complex with dostarlimab, revealing the conformational rearrangements and key residues involved in the high affinity binding. The findings provide valuable information for the design of improved anti-PD-1 biologics and effective combination strategies for cancer immunotherapy.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2022)

添加到收藏夹

Article Oncology

Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study

Ningjing Lin et al.

Summary: GLS-010 (zimberelimab) demonstrates effectiveness and safety in Chinese patients with relapsed or refractory classical Hodgkin lymphoma. The objective response rate assessed by an independent radiology review committee was 90.6%, with a complete response rate of 32.9%. The 12-month progression-free survival and overall survival rates were 78% and 99%, respectively.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Sugemalimab: First Approval

Sohita Dhillon et al.

Summary: Sugemalimab, a fully human monoclonal antibody, has been approved in China for the first-line treatment of EGFR gene mutation and ALK-negative metastatic NSCLC. Clinical studies are also underway to evaluate its efficacy in various other cancer types.

DRUGS (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Nivolumab Plus Relatlimab: First Approval

Julia Paik

Summary: Nivolumab plus relatlimab is a combination immunotherapy treatment being developed for multiple types of advanced cancers. The treatment targets immune checkpoints using monoclonal antibodies. In March 2022, it received its first approval in the USA for unresectable or metastatic melanoma.

DRUGS (2022)

添加到收藏夹

Article Chemistry, Medicinal

Traversing through the Dynamic Protein-Protein InteractionLandscape and Conformational Plasticity of PD-1 for Small-MoleculeDiscovery

Lovika Mittal et al.

Summary: Monoclonal antibodies blocking the PD-1/PD-L1 interface have shown remarkable success in treating malignancies, but they may also initiate lethal immune-related adverse events. Small molecules may circumvent the mAb limitations; however, none has entered clinical trials targeting PD-1. The understanding of PD-1's sequence-structure-dynamic-function link is crucial for exploring its binding mechanisms and discovering new small-molecule drugs.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Oncology

Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case

Antonio Ghidini et al.

Summary: This case report presents an elderly woman with locally advanced squamous carcinoma who showed significant response and good tolerability after receiving Cemiplimab therapy. It demonstrates that immunotherapy is a new treatment option for cSCC.

ORAL ONCOLOGY (2022)

添加到收藏夹

Article Immunology

PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy

Dan Lu et al.

Summary: This study reports the crystal structure of cemiplimab bound to PD-1 and highlights the importance of PD-1 glycosylation in its interaction with cemiplimab. Cemiplimab predominantly binds to PD-1 through its heavy chain, and the N58 glycan on PD-1 is crucial for this interaction. These findings enhance our understanding of the significance of the cemiplimab-PD-1 interaction.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Huilai Lv et al.

Summary: This study evaluated the efficacy and safety of neoadjuvant sintilimab plus chemotherapy in patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC). The results showed that this treatment approach achieved a good pathological complete response rate and had good tolerability.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure

Ning Zan et al.

Summary: This article presents a case report of a patient with metastatic upper tract urinary carcinoma. Long-term clinical response was achieved through immunotherapy combined with antiangiogenesis therapy after unsuccessful surgery and chemotherapy.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Sintilimab for the treatment of non-small cell lung cancer

Lin Zhang et al.

Summary: This study provides an overview of the clinical trials on Sintilimab for non-small cell lung cancer (NSCLC) conducted in China, showing its effectiveness and tolerability, but further research is needed.

BIOMARKER RESEARCH (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Serplulimab: First Approval

Arnold Lee

Summary: Serplulimab, an anti-PD-1 antibody, is an intravenously administered drug developed by Shanghai Henlius Biotech, Inc. for the treatment of solid tumours. It received its first approval in China in 2022 for the treatment of advanced unresectable or metastatic MSI-H solid tumours in adults.

DRUGS (2022)

添加到收藏夹

Article Oncology

Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors

Toshio Shimizu et al.

Summary: This study evaluated the safety, tolerability, pharmacokinetic profile, and efficacy of Envafolimab as a single agent in Japanese patients with advanced solid tumors. The results showed that Envafolimab was well tolerated and demonstrated comparable efficacy to intravenous treatments in Japanese patients. Pharmacokinetic data and preliminary anti-tumor response suggest longer dosing intervals as a more convenient treatment option.

INVESTIGATIONAL NEW DRUGS (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs

Qian Wang et al.

Summary: Cholesterol is crucial for the development and survival of cancer cells. Previous studies have shown that cholesterol-lowering drugs can inhibit the high expression of PD-L1, which contributes to immunoevasion in cancer cells. However, the mechanism of how cholesterol regulates the stability of PD-L1 is still unclear. This study demonstrates that cholesterol can directly bind to PD-L1 through specific amino acid motifs, forming a sandwich-like structure and stabilizing PD-L1 to prevent degradation. These findings reveal a unique regulatory mechanism and provide a potential strategy to overcome PD-L1-mediated immunoevasion in cancer.

SCIENCE ADVANCES (2022)

添加到收藏夹

Article Oncology

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

Dingwei Ye et al.

Summary: Tislelizumab showed meaningful clinical benefits in patients with previously treated PD-L1-positive urothelial carcinoma, with a 24% objective response rate and a durable response rate of 68%. The most common adverse events were anemia and pyrexia.

CANCER SCIENCE (2021)

添加到收藏夹

Article Medicine, General & Internal

ANTI-PD-1 AND ANTI-PD-L1 ANTIBODIES AS IMMUNOTHERAPY AGAINST CANCER: A STRUCTURAL PERSPECTIVE

Luis Cordova-Bahena et al.

Summary: PD-1 and PD-L1 play crucial roles in T cell immunosuppression, with therapeutic antibodies targeting them showing broad clinical applications; however, these targeted therapies are not without adverse effects; understanding the structural domains recognized by antibodies can guide the development of new PD-1 and PD-L1 blocking agents.

REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION (2021)

添加到收藏夹

Article Chemistry, Medicinal

Interplay among Structural Stability, Plasticity, and Energetics Determined by Conformational Attuning of Flexible Loops in PD-1

Lovika Mittal et al.

Summary: The study focuses on the dynamics and plasticity of the PD-1/PD-L1 axis, revealing increased structural stability and coordinated movements in the presence of binding partners. Through computational biophysical approaches, hot-spots essential for arresting the dynamic motions of PD-1 significantly are identified, providing insights for the rational design of therapeutic agents mimicking the mechanism of monoclonal antibodies.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2021)

添加到收藏夹

Review Dermatology

Cemiplimab in advanced cutaneous squamous cell carcinoma

Piyu Parth Naik

Summary: Cemiplimab, a monoclonal antibody targeting PD-1/PD-L1, has demonstrated clinical efficacy and safety in advanced cutaneous squamous cell carcinoma patients, with low rates of treatment discontinuation and death.

DERMATOLOGIC THERAPY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Zimberelimab: First Approval

Anthony Markham

Summary: Zimberelimab is an anti-PD-1 monoclonal antibody approved for marketing in China for the treatment of relapsed or refractory classical Hodgkin's lymphoma. The development of Zimberelimab has gone through several key milestones, leading to its first approval.

DRUGS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Penpulimab: First Approval

Sohita Dhillon

Summary: Penpulimab, a humanised anti-PD-1 monoclonal antibody, has received approval for Hodgkin's lymphoma treatment in China and is undergoing regulatory review for other cancers.

DRUGS (2021)

添加到收藏夹

Article Biochemical Research Methods

Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding

Jong Shin et al.

Summary: The study describes the purification and tight binding of an anti-PD-1 scFv from E. coli to human PD-1, and demonstrates its ability to disrupt the interaction between PD-1 and PD-L1. The properties of this scFv, including its small size, stability, and high affinity for human PD-1, suggest its potential utility in immunotherapeutic, diagnostic, and anti-viral applications.

PROTEIN EXPRESSION AND PURIFICATION (2021)

添加到收藏夹

Article Immunology

Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma

Xuhong Liu et al.

Summary: Combining immunotherapy and targeted therapy can improve the treatment effects of hepatocellular carcinoma. Treatment with sintilimab in combination with sorafenib shows promise in shrinking tumors, but may also lead to immune-related hepatitis.

IMMUNOTHERAPY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy

Hassan Issafras et al.

Summary: Cancer immunotherapies targeting PD-1 have shown promising results, with HLX10 standing out as a potential therapeutic candidate due to its unique mode of recognition and strong anti-tumor activity. The combined inhibition of PD-1/PDL-1 and angiogenesis pathways using HLX10 and anti-VEGF antibody may provide sustained suppression of cancer-related angiogenesis and tumor elimination. Comparisons with clinically approved PD1 antibodies like Pembrolizumab and Nivolumab suggest that HLX10 exhibits similar or better bioactivity, supporting its potential for clinical evaluation in cancer immunotherapy.

PLOS ONE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tislelizumab uniquely binds to the CC′ loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage

Yuan Hong et al.

Summary: Tislelizumab has shown remarkable antitumor efficacy in preclinical models, with structural biology and Surface plasmon resonance (SPR) analyses revealing its unique epitopes and slow dissociation rate from PD-1. The ability of tislelizumab to completely block PD-1/PD-L1 interaction aligns with both structural and functional analyses, broadening our understanding of the mechanism of action of anti-PD-1 antibodies.

FEBS OPEN BIO (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Dostarlimab: First Approval

Anthony Markham

Summary: Dostarlimab, a humanized monoclonal antibody PD-1 receptor antagonist, has been approved for the treatment of various cancers in the EU and USA. This marks a significant milestone in the development of the drug.

DRUGS (2021)

添加到收藏夹

Article Oncology

Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer

Ana Oaknin et al.

Summary: This document summarizes the GARNET trial, which focused on treating patients with dMMR endometrial cancer with dostarlimab and showed efficacy in shrinking tumors in some patients. The percentage of participants experiencing side effects was low and within expectations for this type of treatment.

FUTURE ONCOLOGY (2021)

添加到收藏夹

Article Oncology

RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma

Rong Yu et al.

Summary: Definitive chemoradiotherapy is the standard treatment for inoperable locoregionally advanced esophageal squamous cell carcinoma (ESCC), but the impact of incorporating immune checkpoint inhibitors like tislelizumab in the definitive management of ESCC is still uncertain. The RATIONALE 311 study is a Phase III clinical trial evaluating the efficacy and safety of tislelizumab combined with concurrent chemoradiotherapy in patients with inoperable localized ESCC, aiming to address this question.

FUTURE ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL).

Yuqin Song et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

Jian Li et al.

Summary: Envafolimab demonstrated significant efficacy and acceptable safety in the treatment of previously treated advanced dMMR/MSI-H solid tumors. The objective response rate was 42.7%, disease control rate was 66.0%, and median progression-free survival was 11.1 months.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects

Shima Makaremi et al.

Summary: Immunotherapy is a promising approach in colorectal cancer (CRC) treatment, with checkpoint-blocking antibodies showing promising outcomes. The immunosuppressive tumor microenvironment is a cause of poor treatment response in CRC patients. Combination therapy with immune checkpoint inhibitors (ICIs) shows potential for enhancing immune responses against CRC tumors.

BIOMEDICINES (2021)

添加到收藏夹

Review Medicine, General & Internal

Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer

Ivy Riano et al.

Summary: Pembrolizumab, an immune checkpoint inhibitor, has shown significant efficacy in previously treated patients with extensive-stage small-cell lung cancer. However, its impact on overall survival in untreated patients remains uncertain as the therapeutic landscape for SCLC continues to evolve.

CLINICS AND PRACTICE (2021)

添加到收藏夹

Article Oncology

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

Yuqin Song et al.

LEUKEMIA (2020)

添加到收藏夹

Review Chemistry, Medicinal

Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules

Xin Lin et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Article Oncology

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

Shukui Qin et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Biochemical Research Methods

Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1)

Biyan Wen et al.

PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY (2020)

添加到收藏夹

Article Oncology

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study

R. L. Ferris et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Tislelizumab: First Approval

Arnold Lee et al.

DRUGS (2020)

添加到收藏夹

Article Oncology

Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study

Jianliang Yang et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Toripalimab for the treatment of melanoma

Bixia Tang et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2020)

添加到收藏夹

Article Oncology

Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.

Lin Shen et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

The Combined Use of Chemotherapy and Radiotherapy with PD- I Inhibitor, Pembrolizumab, in Advanced Cervical Cancer: A Case Report

Mengmeng Lyu et al.

ONCOTARGETS AND THERAPY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy

Sang Hyung Lee et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

N-glycosylation of PD-1 promotes binding of camrelizumab

Kefang Liu et al.

EMBO REPORTS (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)

Si-Yang Liu et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

Roy S. Herbst et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Meeting Abstract Oncology

ACTIVITY AND SAFETY OF CAMRELIZUMAB, AN ANTI-PD-1 IMMUNE CHECKPOINT INHIBITOR, FOR PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER

Guo Gui Sun et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

A synopsis of recent developments defining how N-glycosylation impacts immunoglobulin G structure and function

Yoshiki Yamaguchi et al.

GLYCOBIOLOGY (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Sintilimab: First Global Approval

Sheridan M. Hoy

DRUGS (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Toripalimab: First Global Approval

Susan J. Keam

DRUGS (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology

Hyun Tae Lee et al.

MOLECULES (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Camrelizumab: First Global Approval

Anthony Markham et al.

DRUGS (2019)

添加到收藏夹

Article Immunology

Avelumab in gastric cancer

Giandomenico Roviello et al.

IMMUNOTHERAPY (2019)

添加到收藏夹

Article Oncology

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study

Leisha A. Emens et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery

Shaogeng Tang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method

Hocheol Lim et al.

SCIENTIFIC REPORTS (2019)

添加到收藏夹

Article Oncology

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

S. Adams et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Bixia Tang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial

Lillian L. Siu et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Review Urology & Nephrology

A review of avelumab in locally advanced and metastatic bladder cancer

Arpit Rao et al.

THERAPEUTIC ADVANCES IN UROLOGY (2019)

添加到收藏夹

Meeting Abstract Oncology

The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab

Yingcai Feng et al.

CANCER RESEARCH (2019)

添加到收藏夹

Letter Cell Biology

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Shuguang Tan et al.

PROTEIN & CELL (2018)

添加到收藏夹

Article Oncology

The binding of an anti-PD-1 antibody to FcγRI has a profound impact on its biological functions

Tong Zhang et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential

Gonzalo Tapia Rico et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

David F. McDermott et al.

NATURE MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Multidisciplinary Sciences

Cancer immunotherapy using checkpoint blockade

Antoni Ribas et al.

SCIENCE (2018)

添加到收藏夹

Article Oncology

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

Wenfeng Fang et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

L. Horn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Cemiplimab: First Global Approval

Anthony Markham et al.

DRUGS (2018)

添加到收藏夹

Article Oncology

Nivolumab for the treatment of hepatocellular carcinoma

Fabian Finkelmeier et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2018)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

P. Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Oncology

Systemic Therapy for Hepatocellular Carcinoma: Latest Advances

Masatoshi Kudo

CANCERS (2018)

添加到收藏夹

Meeting Abstract Hematology

Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study

Yuqin Song et al.

BLOOD (2018)

添加到收藏夹

Letter Cell Biology

Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy

Kefang Liu et al.

CELL RESEARCH (2017)

添加到收藏夹

Letter Cell Biology

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab

Zhenkun Na et al.

CELL RESEARCH (2017)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

J. Bellmunt et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Multidisciplinary Sciences

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab

Shuguang Tan et al.

NATURE COMMUNICATIONS (2017)

添加到收藏夹

Article Oncology

Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab

Fei Zhang et al.

ONCOTARGET (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Atezolizumab in invasive and metastatic urothelial carcinoma

Michael Crist et al.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)

添加到收藏夹

Article Cell Biology

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade

Fei Zhang et al.

CELL DISCOVERY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab

Hyun Tae Lee et al.

SCIENTIFIC REPORTS (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Durvalumab: First Global Approval

Yahiya Y. Syed

DRUGS (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Atezolizumab: First Global Approval

Anthony Markham

DRUGS (2016)

添加到收藏夹

Review Immunology

Targeting T Cell Co-receptors for Cancer Therapy

Margaret K. Callahan et al.

IMMUNITY (2016)

添加到收藏夹

Article Medicine, General & Internal

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Douglas B. dbj Johnson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

R. L. Ferris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant

Roberta Pascolutti et al.

STRUCTURE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

Ju Yeon Lee et al.

NATURE COMMUNICATIONS (2016)

添加到收藏夹

Review Cell Biology

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies

Shuguang Tan et al.

PROTEIN & CELL (2016)

添加到收藏夹

Review Health Care Sciences & Services

Clinical utility of nivolumab in the treatment of advanced melanoma

Ramsey Asmar et al.

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)

添加到收藏夹

Article Multidisciplinary Sciences

High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1

Shoichiro Horita et al.

SCIENTIFIC REPORTS (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy

Shuguang Tan et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2016)

添加到收藏夹

Review Medicine, General & Internal

Focus on Nivolumab in NSCLC

Diego L. Cortinovis et al.

FRONTIERS IN MEDICINE (2016)

添加到收藏夹

Editorial Material Oncology

Biomarkers in Cancer Immunotherapy

Ton N. Schumacher et al.

CANCER CELL (2015)

添加到收藏夹

Review Immunology

Edelman's view on the discovery of antibodies

Domenico Ribatti

IMMUNOLOGY LETTERS (2015)

添加到收藏夹

Review Oncology

Programmed cell death-1 inhibition in lymphoma

Eliza A. Hawkes et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab

Giovanna Scapin et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)

添加到收藏夹

Letter Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Matias E. Valsecchi

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer

Edward B. Garon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Julie Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

H. Borghaei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Review Multidisciplinary Sciences

The future of immune checkpoint therapy

Padmanee Sharma et al.

SCIENCE (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

Krzysztof M. Zak et al.

STRUCTURE (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab

Giovanna Scapin et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)

添加到收藏夹

Article Pharmacology & Pharmacy

Pembrolizumab: First Global Approval

Raewyn M. Poole

DRUGS (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Roy S. Herbst et al.

NATURE (2014)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Nanobody-based products as research and diagnostic tools

Thomas De Meyer et al.

TRENDS IN BIOTECHNOLOGY (2014)

添加到收藏夹

Review Immunology

IgG subclasses and allotypes: from structure to effector functions

Gestur Vidarsson et al.

FRONTIERS IN IMMUNOLOGY (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structure and Interactions of the Human Programmed Cell Death 1 Receptor

Xiaoxiao Cheng et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2013)

添加到收藏夹

Review Immunology

scFv Antibody: Principles and Clinical Application

Zuhaida Asra Ahmad et al.

CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)

添加到收藏夹

Review Immunology

T cell exhaustion

E. John Wherry

NATURE IMMUNOLOGY (2011)

添加到收藏夹

Article Hematology

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

Mojgan Ahmadzadeh et al.

BLOOD (2009)

添加到收藏夹

Article Oncology

Designing antibodies for the inhibition of gastrin activity in tumoral cell lines

Rodrigo Barderas et al.

INTERNATIONAL JOURNAL OF CANCER (2008)

添加到收藏夹

Article Multidisciplinary Sciences

Affinity maturation of antibodies assisted by in silico modeling

Rodrigo Barderas et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

添加到收藏夹

Article Multidisciplinary Sciences

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

David Yin-Wei Lin et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

添加到收藏夹

Article Multidisciplinary Sciences

Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2

Eszter Lazar-Molnar et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Computational design of antibody-affinity improvement beyond in vivo maturation

Shaun M. Lippow et al.

NATURE BIOTECHNOLOGY (2007)

添加到收藏夹

Review Biochemical Research Methods

Progress in computational protein design

Shaun M. Lippow et al.

CURRENT OPINION IN BIOTECHNOLOGY (2007)

添加到收藏夹

Review Immunology

PD-1 and PD-1 ligands: from discovery to clinical application

Taku Okazaki et al.

INTERNATIONAL IMMUNOLOGY (2007)

添加到收藏夹

Review Immunology

The PD-1-PD-L pathway in immunological tolerance

T Okazaki et al.

TRENDS IN IMMUNOLOGY (2006)

添加到收藏夹

Article Multidisciplinary Sciences

Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies

E De Genst et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)

添加到收藏夹

Review Immunology

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity

LP Chen

NATURE REVIEWS IMMUNOLOGY (2004)

添加到收藏夹

Review Biochemistry & Molecular Biology

Recognition of immunoglobulins by Fcγ receptors

S Radaev et al.

MOLECULAR IMMUNOLOGY (2002)

添加到收藏夹

Article Genetics & Heredity

Heavy-chain antibodies in Camelidae;: a case of evolutionary innovation

VK Nguyen et al.

IMMUNOGENETICS (2002)

添加到收藏夹

Review Hematology

Recombinant monoclonal antibody technology

DL Siegel

TRANSFUSION CLINIQUE ET BIOLOGIQUE (2002)

添加到收藏夹

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1

相关参考文献

导出引文

分享论文